Merck & Co. Inc.'s decision to back away from the Phase II-stage, N-type calcium channel blocker NMED-160 for pain leaves intact its collaboration with privately held Neuromed Pharmaceuticals Inc., and the companies plan to keep working in the same pathway to find another compound. (BioWorld Today) Read More
